Skip to content

Drug Concentrations in Breast Milk and Prediction of Blood Levels of the Breastfed Infants

Drugs in Breast Milk

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05543122
Enrollment
39
Registered
2022-09-16
Start date
2022-03-09
Completion date
2024-03-31
Last updated
2024-04-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Feeding

Brief summary

There is a significant lack of information on drug secretion into milk and infant exposure. As a first step to address this issue, the investigators examine milk concentrations of selected drugs prescribed to breastfeeding women, which lack milk excretion data. Milk data will be analyzed using population pharmacokinetic approaches, when possible, and acquired data of drug concentration profiles in milk will be combined with infant physiologically-based pharmacokinetic (PBPK) models to predict infant exposure levels.

Detailed description

In this study the investigators measure drug concentrations in breast milk (and optional blood) samples collected through sparse and flexible sampling strategy mitigating intense approaches of conventional PK study. Whenever possible, population PK method is used to characterize milk concentration profiles of the selected drugs. The obtained data is further processed through a PBPK model of infant to predict infant drug exposure levels. The study also includes an optional pharmacogenetic part. This will allow the investigators to understand how variations in genetic composition plays role in breaking down drugs and how it affects the drug transfer into breast milk. This study is conducted at three sites: Hospital for Sick Children (leading site), CHU Sainte Justine Hospital, Montreal (Study Lab: for drug measurement), and University of Waterloo (Modelling Core: to create computer model).

Interventions

DRUGeither of Atenolol, Bupropion, Brivaracetam, Escitalopram, Fluconazole, Lacosamide, Lamotrigine, Levetiracetam, Methotrexate or Ezetimibe

This is a cohort study of pharmacokinetics of drugs in milk. Participants in the group are those breastfeeding women on the listed drugs at steady state, who are prescribed these drugs for clinical reasons outside this study framework.

Sponsors

St. Justine's Hospital
CollaboratorOTHER
University of Waterloo
CollaboratorOTHER
The Hospital for Sick Children
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

for breastfeeding women * Age of 18 years or older * Lactating women taking at least one of the study target drugs per Standard of Care * Obtained informed consent * Ability to communicate in English

Exclusion criteria

for breastfeeding women * Any concomitant medication * Known pregnancy during PK sampling Inclusion criteria for their infant * Older than 1 week * Healthy

Design outcomes

Primary

MeasureTime frameDescription
concentrations of target drugs in breast milkan average of 1 yearusing assays of drug concentrations validated in human milk as a matrix

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026